Update shared on11 Sep 2025
Fair value Decreased 39%Despite a substantial increase in consensus revenue growth forecasts, ANGLE’s future P/E multiple has halved, reflecting a notable de-rating and driving the fair value estimate down from £0.28 to £0.17.
What's in the News
- ANGLE plc announced a collaboration with Myriad Genetics, utilising ANGLE's Parsortix system to process cancer patient blood samples for molecular analysis, comparing CTC-DNA with matched tissue samples via Myriad's assay; further details remain confidential.
- A peer-reviewed article published in Nature Genetics, using ANGLE's Parsortix system, found that CTC clusters exhibit significant genetic diversity, which is closely linked to metastasis, therapy resistance, and cancer relapse, highlighting the Parsortix system's ability to identify key cancer cell subpopulations that may be missed by traditional tissue biopsy.
Valuation Changes
Summary of Valuation Changes for ANGLE
- The Consensus Analyst Price Target has significantly fallen from £0.28 to £0.17.
- The Future P/E for ANGLE has significantly fallen from 27.33x to 13.60x.
- The Consensus Revenue Growth forecasts for ANGLE has significantly risen from 138.1% per annum to 163.6% per annum.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.